Prucalopride for the Treatment of Chronic Idiopathic Constipation in Adults

October 18, 2018

Shire

Gastrointestinal Drugs Advisory Committee


Introduction

Sunil Kadam, PhD

Senior Director, Global Regulatory Affairs Shire

Prucalopride is a Next-Generation 5-HT₄ Receptor Agonist With Strong Prokinetic Activity

- Highly-selective 5-HT₄ agonist
- Stimulates colonic peristalsis in patients with CIC to increase intestinal motility¹
- Prucalopride induces high-amplitude propagating contractions



Pressure (mmHg)

Prucalopride is Different from Non-Selective 5-HT₄ Receptor Agonists

Drug	5-HT ₄	5-HT ₃	5-HT ₂	5-HT₁	D_2	hERG
Prucalopride	+					
Cisapride	+	+	+			+
Tegaserod	+	+	+	+		

+ Clinically Relevant Affinity

- Highly selective for 5-HT₄ receptor
- Low potential for off-target effects
- No meaningful affinity for hERG channel
- ECG studies show no effect on QT-prolongation or arrhythmias


Prucalopride Safety Supported by > 8 Years of Pharmacovigilance

- Extensive experience since first approval in 2009
- Marketed in 59 countries
 - Including Canada and countries in EU, Asia and South America
- > 280,000 patient-years experience
- ~ 1 million treated patients

No Updates to CV Safety Within Prucalopride Label Since Launch

- Periodic safety reviews support existing label
 - Annual review by health authorities, including EMA's Pharmacovigilance Risk Assessment Committee (PRAC)
 - Pharmacovigilance of literature and post-marketing data
- No emerging CV safety signals detected since launch

Prucalopride US Development History



76 Clinical Studies Support Prucalopride Benefit-Risk for Chronic Idiopathic Constipation (CIC)

- 16 Phase 3 and 4 studies
 - 2 pivotal
 - 4 supportive
 - 10 additional
- 14 Phase 2 studies
- 46 Phase 1 studies

Prucalopride Safe and Effective for Patients with Chronic Idiopathic Constipation

- Primary endpoint met in 5 of 6 key studies
- Consistent disease characteristics and treatment standards support generalizability to US patients
 - USA studies support safety and efficacy
- Safety well-characterized
 - Supported by clinical studies, post-marketing experience

Proposed Prucalopride Indication

Treatment of chronic idiopathic constipation in adults

- Dosed 2 mg once-daily (QD)
 - Dosed 1 mg QD in patients with severe renal impairment

Agenda

Unmet Need in Chronic Idiopathic Constipation	Michael Camilleri, MD Gastroenterologist and Professor of Medicine, Pharmacology and Physiology Mayo Clinic Rochester, Minnesota
Efficacy	Heinrich Achenbach, MD, PhD Global Clinical Development Team Lead Shire
Safety	John Caminis, MD Therapeutic Area Head - Global Drug Safety Shire
Clinical Perspective	Jan Tack, MD, PhD Professor of Medicine Head of Clinic, Department of Gastroenterology Hospital KU Leuven, Belgium
Conclusion	Debra Silberg, MD, PhD Therapeutic Area Head - VP of Clinical Development Shire

Additional External Experts

Elizabeth Andrews, PhD

Vice President, Pharmacoepidemiology and Risk Management RTI Health Solutions

Peter Kowey, MD

Professor of Medicine and Clinical Pharmacology Jefferson Medical College Emeritus Chair, Cardiology Lankenau Heart Institute

Unmet Need in Chronic Idiopathic Constipation

Michael Camilleri, MD

Gastroenterologist and Professor of Medicine,

Pharmacology, and Physiology

Mayo Clinic

Rochester, Minnesota

Chronic Idiopathic Constipation: Challenging and Persistent Problem^{1,2}

- < 3 complete spontaneous bowel movements (CSBM) per week</p>
- Chronic if lasts for at least 6 months or recurrent
- Idiopathic component frustrating for patients
 - No underlying cause for constipation

¹⁾ Dennison et al., 2005.

²⁾ Peery et al., 2015.

Multiple Effects of CIC Can be Debilitating

- Significant impact on QoL
- Health-related QoL scores comparable to other chronic conditions
 - Musculoskeletal conditions and diabetes¹
 - For women: heart disease, depression²
- May lead to increased risk for complications, comorbidities³
 - Fecal impaction, diverticular disease, rectal prolapse
- Patients reluctant to talk about CIC

¹⁾ Belsey et al., 2010.


²⁾ Wald et al., 2007.

³⁾ Talley et al., 2009.

35 Million US Adults Diagnosed with CIC¹

- Health care costs are considerable
 - All-cause costs = \$11,991, gastro-related costs = \$4,049²
 - > 3 million physician visits every year³
 - 92,000 hospitalizations⁴
 - Several \$100 million expenditures annually on laxatives⁴
- CIC is disruptive
 - Patients missed 0.8 days of school or work per month²
- More prevalent in women, who also more frequently seek treatment⁴
 - > 75% of patients in referral setting are women⁵
- More common in elderly than younger adults⁴

Bowel Movement Categories Differ Based on Initiation and Completeness



(C)(S)BM = (complete) (spontaneous) bowel movements

*CSBM = SCBM

Treatment Goal: Restore Normal Bowel Function (≥ 3 CSBM/week) and Improve Patient Symptoms

- Move stool out of colon, e.g., by accelerating colonic transit¹
- Increased bowel frequency associated with improvements in symptoms
- Achieving ≥ 3 CSBMs per week clinically meaningful and life-changing for patients, both emotionally and physically

Range of Interventions – Lifestyle Modifications, Over-The-Counter, Prescription Therapies

■ No one approach works for all – high patient dissatisfaction¹

LIFESTYLE MODIFICATIONS

- Diet changes
- Increasing fluid intake
- Exercise
- Increase dietary fiber

OVER-THE-COUNTER

- Laxatives (e.g., PEG)
- Bulking agents
- Stool softeners
- Stimulants

PRESCRIPTION THERAPIES


- Prosecretory agents
 - Lubiprostone
 - Linaclotide
 - Plecanatide

(Treatment effect ~8-17%)

Current prescription agents have no direct effect on colonic peristalsis

Propulsion of Colonic Content Regulated in Part by High-Amplitude Propagating Contractions (HAPCs)


- Healthy individuals experience HAPCs about 6 times per day
 - After waking up and eating
 - Followed by urge to defecate
- HAPC frequency reduced in patients with CIC



First Generation, Non-Selective 5-HT₄ Agonists Withdrawn from US Market

- Provided relief to many patients with gut motility dysfunction
 - Safety concerns versus benefits

First Generation 5-HT₄ Agonists Non-Specificity Creates Risk for Off-Target Effects, Potential CV Risk



pKi: Measure of binding affinity expressed as a logarithm DeMaeyer et al., 2008; McKinnell et al., 2013.

Unmet Medical Need for Adults Living with Chronic Idiopathic Constipation

- CIC takes a toll on patients, often live in silence for years
- Once they seek medical help, many still unable to get sustained relief
- Patients looking for safe and effective treatment
 - Increases stool frequency
 - Uses different MoA than secretory agent
 - Improve symptoms

Prucalopride Efficacy Results

Heinrich Achenbach, MD, PhD

Global Clinical Development Team Lead Shire

Primary Efficacy Evidence Supported by 6 Randomized, Double-Blind Placebo-Controlled Studies

Study 3001

(N=501)

12 weeks

Prucalopride (N=249)

Placebo (N=252)

Study 302

(N=374*)

12 weeks

Prucalopride (N=187)

Placebo

(N=187)

Study 6

(N=712)

12 weeks

Prucalopride

(N=236)

Placebo (N=240)

Study USA-11

(N=570)

12 weeks

Prucalopride

(N=190)

Placebo

(N=193)

Study USA-13

(N=641)

12 weeks

Prucalopride

(N=214)

Placebo

(N=212)

Study 401

(N=340)

24 weeks


Prucalopride

(N=171)

Placebo

(N=169)

Phase 3 Study Design



Patients with History of CIC Enrolled Based on Modified Rome Criteria for Functional Constipation

- ≤ 2 spontaneous bowel movements per week
 - Resulting in feeling of complete evacuation (CSBM)
- ≥ 1 of the following in > 25% of BMs
 - Very hard and/or hard stools
 - Sensation of incomplete evacuation
 - Straining at defecation
 - Sensation of anorectal obstruction/blockage
 - Manual maneuvers to facilitate evacuation
- Symptoms must occur
 - ≥ 6 months prior to diagnosis; present during last 3 months

Complete Spontaneous Bowel Movements Clinically Meaningful Outcome in CIC

- Primary endpoint
 - Proportion with average of ≥ 3 CSBMs/week over 12 weeks
- Prespecified secondary and additional endpoints
 - Average increase of ≥ 1 CSBMs per week over 12 weeks
 - Time-to-first SBM

Statistical Powering Assumptions

Assumptions for proportion of patients with average of
 ≥ 3 CSBMs/week

```
    Prucalopride: 27-30% response rate 12-15%
    Placebo: 14-15% response rate Treatment effect
```

All 90% power at 2-sided significance level of 0.05

6 Randomized DBPC Studies Conducted in Different Regions

- USA
 - Studies USA-11, USA-13
- Europe
 - Studies 302, 401
- Global (EU, CAN, ZA, AUS)
 - Study 6
- Asia / Pacific
 - Study 3001

Demographics and Results

Enrolled Populations Varied Across Studies, Balanced Within Each Study

Age

- Mean age 41-58 years (Range 18-75)
- 10-19% age ≥ 65 years (Studies 6, USA-11, USA-13, 401)
- Age ≤ 65 years (Study 3001)

Sex

- 85-93% female (Studies 3001, 6, USA-11, USA-13, 401)
- 100% male (Study 302)

Race


- 86-96% White, 1-11% Black (Studies 302, 6, USA-11, USA-13, 401)
- 92% Asian, 6% White (Study 3001)

Baseline Disease Characteristics Demonstrate Significant CIC


	Study 3001		Study 302		Study 6		Study USA-11		Study USA-13		Study 401	
	Placebo (N=252)										Placebo (N=171)	
Duration of constipation, mean (years)	13	13	9	9	18	16	22	21	21	23	14	16
Baseline CSBMs/week, mean	0.3	0.3	0.4	0.5	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.4

Achieving primary endpoint requires 10-fold improvement


Similar Disposition Across Studies



Primary Endpoint Results Across All Studies Support Benefit of Prucalopride



Prucalopride Response Maintained Throughout Treatment Period




Pooled Data: Study 3001, 302, 6, USA-11, USA-13 and 401

FDA Requested Post-Hoc Analysis: Alternative Endpoint A

- Proportion of patients with
 - ≥ 3 CSBMs/weekAND
 - Increase from baseline of ≥ 1 CSBM/week
 FOR
 - ≥ 9 of 12 weeks, including at least 3 in the last 4 weeks

Alternative Endpoint A Results Consistent with Primary Endpoint Results




Alternative Endpoint A: Proportion of patients with ≥ 3 CSBMs per week and an increase of ≥ 1 CSBM/week for 9 out of 12 weeks including 3 of last 4 weeks


Evaluation Unable to Find Causal Factor for Study 401 Result

- Primary results not statistically significant at Week 12 or 24
- Evaluations of demographics, disease characteristics and rescue medication use unable to explain finding
- Placebo response highest among all prucalopride studies
- Based on powering assumptions, 10% probability that results will not show statistical significance


Higher Proportion of Patients with Average Increase of ≥ 1 CSBM/week




Prucalopride Decreases Time to First SBM



Benefit of Prucalopride Treatment Observed Regardless of Baseline Demographics



Overall Efficacy Evidence Supports Prucalopride Treatment for Patients with CIC



Benefit Observed Across Variety of Secondary and Post-Hoc Efficacy Endpoints

Endpoint	Study 3001	Study 302	Study 6	Study USA-11	Study USA-13	Study 401
Primary endpoint	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	
Alternative Endpoint A	✓	✓	✓	✓	✓	
Average increase of ≥ 1 CSBMs/week	✓		✓	✓	✓	
Time-to-first SBM	√	✓	✓	✓	✓	✓

Prucalopride Safety

John Caminis, MD

Therapeutic Area Head – GI, Endocrine & Metabolism

Global Drug Safety

Shire

Extensive Prucalopride Exposure in Studies and Post-Marketing

	# of Patients Exposed to Prucalopride
Randomized, double-blind, placebo-controlled (DBPC) studies	3,295
Open-label studies	2,759
Phase 1 studies	939
Pharmacoepidemiology Study 802	5,715

Estimated post-marketing exposure through Sept 2017 > 280,000 patient-years experience

Duration of Exposure to Prucalopride From Open-Label Studies

Duration of Prucalopride Exposure in Open-Label	# of Patients With CIC (N=2,759)
Any patient dosed	2,595
≥ 90 days	2,151
≥ 180 days	1,710
≥ 365 days	1,052

Additional Safety Data Collected During Open-Label Studies

- 86% of DBPC patients continued into open-label extension
- Data collected every 3 months
 - Adverse events
 - ECG
 - Vital signs
 - Laboratory data
 - Pharmacokinetic (months 3, 6 and 9)

Pooled Randomized DBPC: 16 Studies of ≥ 4 Weeks

- Phase 3 and 4 (n=9)
- Phase 2 (n=7)
- Safety assessment focused on
 - Placebo (N=1,973)
 - Prucalopride 2 mg (N=1,516)

Pooled Randomized DBPC: Most AEs Reported as Mild or Moderate, With Few SAEs

	Placebo (N=1,973)	Prucalopride 2 mg (N=1,516)
Any AE	54%	62%
Any severe AE	11%	13%
Any serious AE	2%	2%
Any AE leading to discontinuation	3%	5%
Death	0.05%	0.07%

Pooled Randomized DBPC:4 AEs Reported in ≥ 5% of Patients

	Placebo (N=1,973)	Prucalopride 2 mg (N=1,516)
Any AE	54%	62%
Headache	9%	17%
Nausea	6%	14%
Diarrhea	4%	12%
Abdominal pain	8%	10%

Majority of events mild or moderate, and typically transient in nature

Pooled Randomized DBPC: Low Rate of AEs Leading to Discontinuation (≥ 1%)

	Placebo (N=1,973)	Prucalopride 2 mg (N=1,516)
Any AE leading to discontinuation	3%	5%
Headache	0.5%	1.5%
Diarrhea	0.1%	1.5%
Nausea	0.5%	1.3%

All Deaths: 3 from Pooled Randomized DBPC (N=5,278) 5 from Open-Label (N=2,759)

Age / Sex	Cause of Death	Dose	Studies	Treatment
89 / M	MI	Placebo	DBPC	On
83 / M	Lobar pneumonia	1 mg	DBPC	On
86 / F	Bronchitis	2 mg	DBPC	On
81 / M	MI	2 mg	Open-label	Off drug + 67 days
89 / F	Pneumonia	2 mg	Open-label	On
56 / M	MI	4 mg	Open-label	On
70 / M	Suicide	2 mg	Open-label	Off drug + 29 days
40 / F	Suicide	4 mg	Open-label	Off drug + 52 days

Evaluation of Suicide-Related Events Concluded No Changes to Prucalopride Safety Information

DBPC: Low incidence of psychiatric AEs and similar to placebo

Age/Sex	Event	Studies	Relevant History	Treatment Duration
70 / M	Suicide	Open-label	Depression, insomnia anti-depressants 1 mo prior to event	101 days + 29 days off drug
40 / F	Suicide	Open-label	Depression, drug abuse	242 days + 52 days off drug
29 / F	Suicide Attempt	DBPC	Depression; illicit drug use	42 days + 7 days off drug
38 / F	Suicide Attempt	Open-label	None documented: personal problems	269 days
37 / F	Suicide Attempt	Open-label	Anxiety, multiple pain diagnoses, psychiatric & pain medications	142 days
24 / M	Suicide Ideation	Open-label	Depression, insomnia, hallucinations, homicidal thoughts	452 days

None of the events attributed to prucalopride

Cardiovascular and Major Adverse Cardiac Events (MACE) Assessments


Comprehensive Assessments Support Prucalopride CV Safety

- 1. Extensive nonclinical testing at supra-therapeutic doses
- 2. Thorough QT study and Phase 1 monitoring
- 3. Comprehensive review of pooled randomized DBPC studies
- 4. Independent, blinded expert adjudication of MACE in randomized DBPC and open-label clinical studies
- 5. Pharmacoepidemiology Study 802 comparing patients treated with prucalopride to patients treated with PEG
- 6. More than 8 years post-marketing safety experience

52 Receptors Tested for Binding Affinity (pKi)

- 14 5-HT receptor subtypes
- 13 monoamine receptors
- 8 peptide receptors
- 5 ion channels
- 5 transporters
- 3 opiate receptors
- 4 other

Prucalopride is a Highly-Selective, High-Affinity 5-HT₄ Receptor Agonist (pKi)



pKi: Measure of binding affinity expressed as a logarithm DeMaeyer et al., 2008; McKinnell et al., 2013.

Nonclinical Evidence Show Wide Cardiovascular Safety Margin¹ and Absence of Mechanism for CV Risk

- No relevant effect on electrophysiological parameters
 - No effect on hERG channel at 50-times therapeutic concentration
 - No effects on other ion channels at 500-times therapeutic concentration
 - No proarrhythmic tendencies observed at 500-times therapeutic concentration
- No effect on platelet aggregation or coronary artery contractility

TQT & Phase 1 Studies In Healthy Volunteers: No Effect on Cardiac Repolarization or Proarrhythmic Potential

- Phase 1 studies up to 20 mg with intense cardiac monitoring
- TQT studied doses 2 and 10 mg
 - No effects on repolarization
 - No electrophysiological change
- Transient change in heart rate
 - No further increases at higher doses 20mg

Comprehensive Assessments Support Prucalopride CV Safety

- 1. Substantive nonclinical testing at supra-therapeutic doses
- 2. Thorough QT study and Phase 1 monitoring
- 3. Comprehensive review of pooled randomized DBPC studies
- 4. Independent, blinded expert adjudication of MACE in randomized DBPC and open-label clinical studies
- 5. Pharmacoepidemiology Study 802 comparing patients treated with prucalopride to patients treated with PEG
- 6. More than 8 years post-marketing experience

16 Pooled Randomized DBPC and 3 Open-Label Studies: Low Incidence of CV AEs of Interest

	Prucalopride Prucalopride		
	Placebo (N=1,973)	2 mg (N=1,516)	Open-Label* (N=2,759)
Exposure time (patient-years)	389	327	2302
QT Prolongation, Ventricular Arrhythmia & Syncope			
Any AE	2.8%	1.8%	1.4%
Any serious AE	0.5%	0.3%	0.2%
Any death	0	0	0
Any AE leading to discontinuation	0	0	0.1%
Cardiovascular & Cerebrovascular Ischemic Events			
Any AE	1.3%	1.8%	1.0%
Any serious AE	0.8%	0.6%	0.6%
Any death	0.2%	0	0.9%
Any AE leading to discontinuation	0.5%	0.3%	0.9%

^{*} Total includes all prucalopride doses from 7 open-label studies (3, 4, 10, BEL-8, FRA-1, NED-4, USA-22)

16 Pooled Randomized DBPC and 3 Open-Label Studies: Low Frequency of Ischemic Events

	Placebo	Open-Label*	
	(N=1,973)	Prucalopride (N=3,305)	(N=2,759)
CV ischemic-related AE, N (%)	5 (0.3%)	9 (0.3%)	23 (0.8%)
Events/100 years exposure	1.3	1.6	1.0

^{*} Total includes all prucalopride doses from 7 open-label studies (3, 4, 10, BEL-8, FRA-1, NED-4, USA-22)

Independent Adjudication of Randomized DBPC Data Found No Indication of an Increased MACE Risk

	Placebo (N=2,019)	Total Prucalopride* (N=3,366)	Prucalopride 2 mg (N=1,516)
MACE	2 (0.1%)	2 (0.1%)	1 (0.1%)
CV death	0.05%	0	0
Non-fatal MI	0	0.03%	0
Non-fatal stroke	0.05%	0.03%	0.06%
MACE rate / 1000 patient years	5.2	3.5	3.1
Extended MACE (with unstable angina)	2 (0.1%)	4 (0.1%)	1 (0.1%)
Extended MACE rate / 1000 PYE	5.2	7.1	3.1

~31% of enrolled patients with pre-existing CV condition or disease

^{*} Total includes all prucalopride doses for Pooled 16 Randomized DBPC studies ≥ 4 weeks plus 3 randomized DBPC studies < 4 weeks Pooled Randomized DBPC (Studies 3001, 302, 6, USA-11, 12, USA-13, USA-25, USA-28, 401, 1, FRA-1, 2, USA-3, GBR-4, BEL-6, USA-26); plus randomized DBPC < 4 weeks duration (Studies NED-2, NED-13, USA-21)

Comprehensive and Systematic Assessments Support Prucalopride CV Safety

- 1. Substantive nonclinical testing at supra-therapeutic doses
- 2. Thorough QT study and Phase 1 monitoring
- 3. Comprehensive review of pooled randomized DBPC studies
- 4. Independent, blinded expert adjudication of MACE in randomized DBPC and open-label clinical studies
- 5. Pharmacoepidemiology Study 802 comparing patients treated with prucalopride to patients treated with PEG
- 6. More than 8 years post-marketing experience

Study 802: Robust Pharmacoepidemiology Population-Based Study

- Comparing incidence of MACE for prucalopride and PEG
 - Designed to exclude three-fold relative risk of MACE for prucalopride
- Data collected 2010-2016
 - 5 data sources from UK, Sweden and Germany
- Pooled results included data from UK and Sweden
 - Matching and propensity scores resulted in cohorts well-balanced in demographics and CV risk factors


Study 802: Demographic Characteristics

	Prucalopride	PEG
	(N=5,715)	(N=29,372)
Sex		
Female	93%	93%
Male	7%	7%
Age (years)		
18 - 54	57%	58%
≥ 55	43%	42%
Age (years) and sex		
≥ 55 Female	39%	38%
≥ 55 Male	4%	4%
History of CV hospitalization		
Yes	6%	5%
At least 1 cardiovascular risk factor		
Yes	58%	55%

Study 802: No Increased Risk for MACE Compared to Patients Treated with PEG (Primary Analysis)

MACE	Prucalopride (N=5,715)	PEG (N=29,372)
Adjusted incidence rate / 1000 patient years (95% CI)	6.57 (3.90, 10.39)	10.24 (6.97, 14.13)
Adjusted incidence rate ratio (95% CI)	0.64 (0.36, 1.14)	

Study 802: Subgroup Analyses Align with Overall Results



Study 802: Conclusion

- Did not establish increased risk of MACE with prucalopride compared to PEG
- Overall sensitivity analyses support results of primary endpoint
 - Varying outcome definitions and follow-up time
 - Analysis of potential bias

Comprehensive and Systematic Assessments Support Prucalopride CV Safety

- 1. Substantive nonclinical testing at supra-therapeutic doses
- 2. Thorough QT study and Phase 1 monitoring
- 3. Comprehensive review of pooled randomized DBPC studies
- 4. Independent, blinded expert adjudication of MACE in randomized DBPC and open-label clinical studies
- 5. Pharmacoepidemiology Study 802 comparing patients treated with prucalopride to patients treated with PEG
- 6. More than 8 years post-marketing experience

Safety Profile Supported by More Than 280,000 Patient-Years Exposure (2009 – 2017*)

- Continuous monitoring and signal detection across all available sources of published and post-marketing data
- N=5,072 reported adverse events
 - 151 cardiovascular events
 - Majority non-serious
 - No change in annual reported rate since 2009

No Change to CV Safety Profile Since Launch

- Shire implemented active monitoring for CV events
 - Desire for caution based on CV reports for other non-specific 5-HT₄ products
- Periodic review by Heath Authorities Bodies (e.g., EMA's PRAC)
 - Responsible for assessing all aspects of pharmacovigilance and risk management
- No CV safety signal identified from any agency

Prucalopride Maintains Positive Benefit Risk Profile Since Launch

- Core safety information on cardiovascular risk unchanged since launched in 2009
- Most commonly reported AEs: Headache, nausea, diarrhea and abdominal pain
- Most AEs were mild to moderate in severity, occurred early and were transient in nature
- Comprehensive investigation of individual sources of data did not reveal an increase in CV risk for prucalopride
- Totality of data did not identify increase in CV risk

Clinical Perspective on Prucalopride

Jan Tack, MD, PhD


Professor of Medicine

Head of Clinic, Department of Gastroenterology University Hospital KU Leuven, Belgium


Prucalopride Delivers Clinically Meaningful Outcomes for Patients with CIC

- Low rate of BMs = low QoL and high symptom severity
- Majority of refractory patients unable to achieve relief from laxatives
- With prucalopride
 - More than 1/3 patients achieve ≥ 3 CSBMs/week
 - Patients report symptom improvement with any increase in CSBMs
 - Improve quality of life

Patient Satisfaction Extends Beyond 3 CSBMs



Prucalopride Improves Difficult-to-Manage Symptoms




Daily Regularity Important for Patients and Result of Prucalopride's Mechanism of Action

- Prucalopride's physiological response reflects MoA
 - Not seen with other treatments
- Patients generally have bowel movement in morning
- Becomes normal stool pattern
 - No longer worry about when, or stay close to bathroom

Prucalopride Induces Colonic High Amplitude Propagating Contractions (HAPC), Alleviating CIC

- Patients with CIC have fewer HAPCs
- Contractions greater in patients with constipation taking Prucalopride than PEG
 - HAPC frequency similar to healthy volunteers
- More HAPCs corresponds with increase in BMs



Managing Risks in Practice

- Inform patients about headache, diarrhea and abdominal symptoms
 - Usually transient
 - Rarely cause discontinuation

Prucalopride Fills Gap in Treatment Landscape

- Available therapeutic options mainly target secretion
- Prucalopride's unique MoA addresses motility
- Patients can experience
 - Increased stool frequency
 - Ease and regularity of defecation
 - Decrease in abdominal symptoms
 - Increase in satisfaction
- Safe and well-tolerated

Concluding Remarks

Debra Silberg, MD, PhD

Therapeutic Area Head – VP of Clinical Development Shire

Unique NDA

- Real world experience since 2009
- Available in 59 countries
- ~ 1 million patients have taken prucalopride
- Post-marketing experience supports use of pharmacoepidemiology study to examine CV safety
 - Rather than prospective 12-month RCT

> 8 Years of Dedicated Post-Marketing CV Monitoring Finds No Signal for CV Events in Patients

- Includes pharmacovigilance and pharmacoepidemiology
 Study 802, specifically designed to look at CV events
- No changes in CV safety profile since approval

Real World Data Supported by Large Development Program

- Nonclinical and Phase 1 studies show no biologic plausibility for cardiovascular risk
- Double blind placebo controlled trials and long-term extension studies showed low rates of CV events

Totality of Data Supports Prucalopride's Positive Benefit/Risk Profile

- Prucalopride is a highly selective, 5-HT₄ receptor agonist
- Promotes high amplitude propagating contractions
- Pro-kinetic agent would give new, efficacious treatment option with different MoA
- Approval would fill gap for treating CIC and provide relief for many patients

Q&A Moderator

Debra Silberg, MD, PhD

Therapeutic Area Head – VP of Clinical Development Shire

Prucalopride for the Treatment of Chronic Idiopathic Constipation in Adults

October 18, 2018

Shire

Gastrointestinal Drugs Advisory Committee

Backup Slides Shown

Post Marketing: Cases Reporting Concomitant GI Medication use with Prucalopride


	Post Marketing Cases			
GI medication	Cases	Serious Cases		
Lactulose	20	4		
Senna/Senokot	13	3		
Laxatives	10	1		
Bisacodyl	9	2		
Magnesium/magnesium oxalate/magnesium glycinate	6	2		
Psyllium	3	0		
PEG / Polyethylene glycol	2	1		
Linaclotide/Linzess	0	0		
Plecanatide/Trulance	0	0		
Lubiprostone/Amitiza	0	0		

There were patients who were taking more than 1 concomitant medication.

Summary of Adverse Events Phase II / IV DBPC Studies

		Prucalopride			
	Placebo (N=1,973)	2 mg (N=1,516)	4 mg (N= 1,349)	Total (N=3,305)	
AEs	54%	62%	71%	65%	
Severe AEs	11%	13%	20%	16%	
Related AEs	21.5%	35.3%	44%	37.9%	
Serious AEs	2%	2%	2%	2%	
AEs leading to discontinuation	3%	5%	9%	7%	
Deaths (n)	1	1	0	2	

Primary Endpoint Effect Size by Race



Pooled Data: Study 3001, 302, 6, USA-11, USA-13 and 401

Race Distribution of Patients on Prucalopride

CIC Open Label Studies

Race	N (%)		
White	2509 (90.9)		
Black or African American	189 (6.9)		
Native Hawaiian or other Pacific Islander	None		
Asian	13 (0.5)		
American Indian or Alaska Native	None		
Multiple	1 (0.06)		
Other	47 (1.7)		

6 Key Efficacy Studies

Race*	N (%)		
White	2551 (79.5)		
Black or African American	112 (3.5)		
Native Hawaiian or other Pacific Islander	None		
Asian	480 (15.0)		
American Indian or Alaska Native	None		
Multiple	None		
Other	48 (1.5)		

^{* 18} missing

Methodology of Adjudication for MACE in DBPC Studies

- Objective: To evaluate all potential major adverse cardiovascular events (MACE) from completed Phase 2/4 clinical studies in adult subjects
- External adjudication committee Membership
 - 2 cardiologists and 1 stroke neurologist
 - retrospectively reviewed cases in a blinded manner using consistent endpoint definitions to adjudicate potential MACE
 - Process
 - The Endpoint Coordinating Team (ECT) included appointees from a CRO and Shire to ensured that all reported potential events were provided to the expert committee and adjudicated
 - The Chair of the External Adjudication Committee received a listing of SAEs and selected relevent Events for Adjudication


Total ¹⁴C-labeled Prucalopride Tissue Distribution as % of Dose: Male Wistar Rats, Single Oral Dose (0.63 mg base-eq/kg)

Group code Time (h)	C 0.5	D 1	E 2	F 4	G 8	H 24	l 48	J 96
Brain	0.015 ± 0.002	0.014 ± 0.001	0.010 ± 0.003	0.006 *	≤0.004	≤0.004	≤0.004	≤0.004
Heart	0.099 ± 0.015	0.070 ± 0.021	0.048 ± 0.006	0.023 ± 0.006	0.006 ± 0.004	≤0.003	≤0.002	≤0.002
Lung	0.240 ± 0.038	0.183 ± 0.044	0.147 ± 0.034	0.072 ± 0.019	0.022 ± 0.011	≤0.003	≤0.003	≤0.003
Liver	15.6 ± 2.0	14.0 ± 1.4	11.2 ± 1.4	6.86 ± 1.20	2.55 ± 0.49	0.719 ± 0.090	0.360 ± 0.037	0.207 ± 0.020
Kidney	0.808 ± 0.100	0.598 ± 0.138	0.397 ± 0.037	0.207 ± 0.057	0.067 ± 0.018	0.014 ± 0.002	0.010 ± 0.002	0.007 ± 0.001
Adrenal gland	0.006 ± 0.002	0.006 ± 0.001	0.004 ± 0.001	≤0.002 *	≤0.002 *	≤0.002	≤0.002	≤0.002
Stomach (tissue)	0.355 ± 0.036	0.245 ± 0.054	0.169 ± 0.046	0.060 ± 0.022	0.021 ± 0.016	≤0.003	≤0.003	≤0.003
Stomach (contents)	27.7 ± 4.4	17.0 ± 4.5	9.44 ± 9.69	2.40 ± 3.60	1.97 ± 2.56	≤0.03	≤0.03	≤0.03
Small intestine (tissue)	8.15 ± 1.09	6.79 ± 0.76	5.54 ± 1.11	1.65 ± 0.450	0.452 ± 0.305	0.010 *	≤0.02	≤0.02
Sm intestine (contents)	24.1 ± 2.5	33.3 ± 0.4	41.9 ± 6.8	16.6 ± 1.9	2.49 ± 0.43	0.114 ± 0.026	≤0.03	≤0.03
Large intestine (tissue)	0.322 ± 0.055	0.249 ± 0.055	0.220 ± 0.036	0.527 ± 0.079	0.292 ± 0.070	0.022 ± 0.001	≤0.006	≤0.006
Lrg intestine (contents)	0.546 ± 0.103	1.11 ± 0.15	2.14 ± 1.03	36.6 ± 1.8	33.5 ± 8.8	2.19 ± 0.061	0.074 ± 0.061	≤0.03


Results of Nonclinical in vitro and in vivo CNS Studies Using Supra-Therapeutic Prucalopride Doses

- Low levels of ¹⁴C-prucalopride and its metabolites in brain (total radioactivity <0.02% of total dose in male rats at all time points to 8 hrs)
- No affinity for a wide array of receptors, ion channels, and monoamine transporters at neurotransmitter sites (>150x)
- No structural relationships to controlled drug substances
- Safety pharmacology studies in rats and mice, CNS-related observations were noted at very high concentrations (≥390x)
- Toxicology studies in rats and dogs, CNS-related observations were observed at very high concentrations (≥325x)

QOL Data from Phase 3 Open-Label Studies Confirm Long-Term Prucalopride Efficacy



Summary 5 Key Efficacy Studies (Without Study 401)



Completed Formal DDI Studies

Effect of prucalopride on other drugs (in vivo interaction studies):

- Warfarin
- Digoxin
- Alcohol
- Erythromycin
- Paroxetine
- Ethinylestradiol / norethisterone

Effect of other drugs on prucalopride (in vivo interaction studies):

- Probenecid
- Cimetidine
- Erythromycin
- Ketoconazole
- Paroxetine